| Literature DB >> 35184359 |
Nirajmohan Shivaperumal1, Daniel R Knight2, Korakrit Imwattana1, Grace O Androga1, Barbara J Chang1, Thomas V Riley1,2,3,4.
Abstract
BACKGROUND AND AIMS: Clostridium (Clostridiodes) difficile clade 3 ribotype (RT) 023 strains that fail to produce black colonies on bioMérieux ChromID agar have been reported, as well as variant strains of C. difficile that produce only toxin A. We have recently isolated strains of C. difficile from the environment in Western Australia (WA) with similar characteristics. The objective of this study was to characterize these strains. It was hypothesized that a putative β-glucosidase gene was lacking in these strains of C. difficile, including RT 023, leading to white colonies. METHODS ANDEntities:
Keywords: zzm321990Clostridium (Clostridioides) difficilezzm321990; clade-III; environment; esculin hydrolysis negative; putative β glucosidase gene; toxin A variant; whole-genome sequencing
Mesh:
Substances:
Year: 2022 PMID: 35184359 PMCID: PMC9544920 DOI: 10.1111/jam.15500
Source DB: PubMed Journal: J Appl Microbiol ISSN: 1364-5072 Impact factor: 4.059
Summary of C. difficile and comparator strains analysed in this study
| Strain | Ribotype | Toxin profile | Sequencetype | Reference | Source |
|---|---|---|---|---|---|
| HGP05 | 125 | A‐B‐CDT‐ | 848 | Shivaperumal et al. ( | Soil |
| HGP07 | UNIQUE | A‐B‐CDT‐ | 849 | Shivaperumal et al. ( | Soil |
| HGP14 | QX597 | A + B‐CDT‐ | 632 | Shivaperumal et al. ( | Soil |
| HGP19 | 125 | A‐B‐CDT‐ | 848 | Shivaperumal et al. ( | Soil |
| HGP28 | QX639 | A‐B‐CDT‐ | 850 | Shivaperumal et al. ( | Soil |
| HGP30 | QX597 | A + B‐CDT‐ | 632 | Shivaperumal et al. ( | Soil |
| HGP33 | QX597 | A + B‐CDT‐ | 632 | Shivaperumal et al. ( | Shoe sole |
| HGP34 | QX638 | A‐B‐CDT‐ | 851 | Shivaperumal et al. ( | Soil |
| HGP35 | QX639 | A‐B‐CDT‐ | 850 | Shivaperumal et al. ( | Soil |
| HGP43 | 125 | A‐B‐CDT‐ | 848 | Shivaperumal et al. ( | Compost |
| HGP46 | QX637 | A‐B‐CDT‐ | 852 | Shivaperumal et al. ( | Soil |
| HGP47 | UNIQUE | A‐B‐CDT‐ | 853 | Shivaperumal et al. ( | Soil |
| HGP48 | QX637 | A‐B‐CDT‐ | 852 | Shivaperumal et al. ( | Soil |
| HGP71 | 125 | A‐B‐CDT‐ | 848 | Shivaperumal et al. ( | Compost |
| HGP78‐1 | QX597 | A + B‐CDT‐ | 632 | Shivaperumal et al. ( | Soil |
| HGP78‐2 | 125 | A‐B‐CDT‐ | 848 | Shivaperumal et al. ( | Soil |
| HGP79 | 125 | A‐B‐CDT‐ | 848 | Shivaperumal et al. ( | Compost |
| R8375 | 002 | A+B+CDT− | N/A | ECDC | |
| Clos di 21 | 023 | A+B+CDT+ | N/A | ECDC | |
| R11446 | 014 | A+B+CDT− | N/A | ECDC | |
| 2149/ATCC 43600 | 014 | A+B+CDT− | N/A | ECDC | |
| 1470 / ATCC 43598 | 017 | A−B+CDT− | N/A | ECDC | |
| R10725 | 078 | A+B+CDT+ | N/A | ECDC | |
| R20291 / NCTC 13366 | 027 | A+B+CDT+ | N/A | ECDC | |
| VPI 10463 / ATCC 43255 | 087 | A+B+CDT− | N/A | ECDC | |
| CD630 / ATCC BAA‐1382™ | 012 | A+B+CDT− | N/A | ECDC | |
| ES1213 | 251 | A+B+CDT+ | Wehrhahn et al. ( | Human |
FIGURE 1C. difficile colonies on C. difficile ChromID agar. Standard black colonies produced by esculin hydrolysis‐positive strains of C. difficile clade 1 (RT012), clade 2 (RT027), clade 4 (RT017), clade 5 (RT078) and garden strain‡ RT010, on ChromID. Colourless colonies produced by esculin hydrolysis‐negative strains of C. difficile clade 3 (RT023) and garden strain QX597
FIGURE 2Growth kinetics of esculin hydrolysis‐negative and reference strains. The growth of strain clos di 21 (RT023), VPI10463 (RT087), CD630 (RT012), VPI11186 (RT038) and esculin hydrolysis strains was measured by OD600 up to 36 h
Antimicrobial susceptibility analysis
| Strain | Antimicrobial breakpoint (mg/L) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDX | VAN | MTZ | RIF | CLI | ERY | AMC | MXF | MEM | |||||||||||||||||||
| S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | |
| ‐ | ‐ | ≥1 | ≤2 | ‐ | >2 | ≤2 | ‐ | >2 | ≥32 | ≤2 | 4 | ≥8 | ‐ | ‐ | >8 | ≤4 | 8 | ≥16 | ≤2 | 4 | ≥8 | ≤4 | 8 | ≥16 | |||
| HGP05 | 0.12 | 2 | 0.25 | 2 | 4 | 0.5 | 0.25 | 1 | 4 | ||||||||||||||||||
| HGP07 | 0.25 | 2 | 0.5 | 2 | 2 | 0.5 | 0.5 | 1 | 4 | ||||||||||||||||||
| HGP14 | 0.12 | 2 | 0.25 | 4 | 2 | 1 | 0.25 | 2 | 4 | ||||||||||||||||||
| HGP19 | 0.25 | 2 | 0.5 | 1 | 0.5 | 0.5 | 0.5 | 1 | 4 | ||||||||||||||||||
| HGP28 | 0.25 | 2 | 0.5 | 4 | 0.5 | 1 | 0.5 | 2 | 8 | ||||||||||||||||||
| HGP30 | 0.25 | 2 | 0.25 | 4 | 4 | 1 | 0.25 | 1 | 4 | ||||||||||||||||||
| HGP33 | 0.25 | 2 | 0.25 | 4 | 4 | 1 | 0.25 | 2 | 4 | ||||||||||||||||||
| HGP34 | 0.12 | 2 | 0.5 | 4 | 2 | 0.5 | 0.5 | 1 | 4 | ||||||||||||||||||
| HGP35 | 0.12 | 2 | 0.5 | 2 | 0.5 | 1 | 0.5 | 2 | 8 | ||||||||||||||||||
| HGP43 | 0.12 | 2 | 0.5 | 4 | 2 | 0.5 | 0.5 | 1 | 4 | ||||||||||||||||||
| HGP46 | 0.12 | 1 | 0.5 | 8 | 2 | 1 | 0.5 | 1 | 8 | ||||||||||||||||||
| HGP47 | 0.12 | 2 | 0.25 | 1 | 4 | 1 | 0.5 | 1 | 4 | ||||||||||||||||||
| HGP48 | 0.25 | 1 | 0.5 | 8 | 2 | 1 | 0.5 | 1 | 4 | ||||||||||||||||||
| HGP71 | 0.12 | 2 | 0.5 | 4 | 0.5 | 0.25 | 0.5 | 1 | 4 | ||||||||||||||||||
| HGP78‐1 | 0.25 | 2 | 0.25 | 4 | 8 | 1 | 0.25 | 1 | 4 | ||||||||||||||||||
| HGP78‐2 | 0.25 | 2 | 0.5 | 4 | 4 | 0.5 | 0.5 | 1 | 4 | ||||||||||||||||||
| HGP79 | 0.06 | 2 | 0.25 | 0.5 | 1 | 0.25 | 0.5 | 1 | 4 | ||||||||||||||||||
|
| 0.015 | 2 | 0.125 | 0.004 | 8 | 1 | 0.5 | 2 | 2 | ||||||||||||||||||
|
| >4 | >4 | 0.5 | 0.25 | 1 | 16 | 0.25 | 0.25 | <0.25 | ||||||||||||||||||
|
| 0.03 | 2 | 0.25 | 0.06 | 0.125 | 0.25 | 0.5 | 0.25 | 0.5 | ||||||||||||||||||
|
| >4 | >4 | >4 | 1 | 2 | 16 | 0.25 | 1 | <0.25 | ||||||||||||||||||
Note: S, susceptible; I, intermediate; R, resistant. ATCC700057 (C. difficile) and ATCC25285 (Bacteroides fragilis) strains were controls as recommended by CLSI. FDX, fidaxomicin; VAN, vancomycin; MTZ, metronidazole; RIF, rifampin; CLI, clindamycin; ERY, erythromycin; AMC, amoxicillin‐clavulanate; MXF, moxifloxacin; MEM, meropenem.
Breakpoints for fidaxomicin recommended by EMA (report WC500119707, http://www.ema.europe.eu/) (European Medicines Agency, 2011), for vancomycin and metronidazole recommended by EUCAST (EUCAST, 2020), remaining as recommended by CLSI (CLSI, 2013).
Genome metrics
| Strain | ENA accession | N contigs | Total length (bp) | N50 (bp) | GC (%) | Median seq depth |
|---|---|---|---|---|---|---|
| HGP05 | SAMN22374628 | 13 | 4,138,029 | 3,844,413 | 28.48 | 55.26 |
| HGP07 | SAMN22374629 | 14 | 4,119,880 | 3,757,367 | 28.51 | 77.33 |
| HGP14 | SAMN22374630 | 81 | 4,241,508 | 93,313 | 28.45 | 99.15 |
| HGP19 | SAMN22374631 | 14 | 4,136,262 | 3,782,574 | 28.45 | 45.83 |
| HGP28 | SAMN22374632 | 12 | 4,243,128 | 3,951,787 | 28.38 | 36.77 |
| HGP30 | SAMN22374633 | 92 | 4,265,720 | 92,878 | 28.42 | 101.48 |
| HGP33 | SAMN22374634 | 13 | 4,249,315 | 3,787,856 | 28.48 | 80.19 |
| HGP34 | SAMN22374635 | 11 | 4,237,441 | 2,696,177 | 28.44 | 68.39 |
| HGP35 | SAMN22374636 | 16 | 4,241,733 | 3,836,539 | 28.38 | 33.77 |
| HGP43 | SAMN22374637 | 13 | 4,137,439 | 3,843,029 | 28.47 | 93.05 |
| HGP46 | SAMN22374638 | 9 | 4,192,908 | 3,967,814 | 28.23 | 48.57 |
| HGP47 | SAMN22374639 | 12 | 4,511,861 | 4,285,437 | 28.33 | 29.15 |
| HGP48 | SAMN22374640 | 10 | 4,206,389 | 3,980,098 | 28.28 | 107.63 |
| HGP71 | SAMN22374641 | 13 | 4,146,017 | 3,852,144 | 28.47 | 60.05 |
| HGP78‐1 | SAMN22374642 | 77 | 4,485,801 | 104,641 | 28.24 | 95.72 |
| HGP78‐2 | SAMN22374643 | 13 | 4,171,210 | 3,877,171 | 28.41 | 28.68 |
| HGP79 | SAMN22374644 | 13 | 4,181,177 | 3,842,470 | 28.42 | 38.25 |
MLST data
| Strain | ST | Clade |
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| HGP05 | 848 | C‐III | 86 | 89 | 86 | 125 | 73 | 100 | 106 |
| HGP07 | 849 | C‐III | 87 | 89 | 86 | 125 | 73 | 101 | 106 |
| HGP14 | 632 | C‐III | 57 | 61 | 61 | 90 | 50 | 71 | 83 |
| HGP19 | 848 | C‐III | 86 | 89 | 86 | 125 | 73 | 100 | 106 |
| HGP28 | 850 | C‐III | 88 | 39 | 54 | 57 | 74 | 50 | 56 |
| HGP30 | 632 | C‐III | 57 | 61 | 61 | 90 | 50 | 71 | 83 |
| HGP33 | 632 | C‐III | 57 | 61 | 61 | 90 | 50 | 71 | 83 |
| HGP34 | 851 | C‐III | 89 | 90 | 87 | 126 | 75 | 102 | 107 |
| HGP35 | 850 | C‐III | 88 | 39 | 54 | 57 | 74 | 50 | 56 |
| HGP43 | 848 | C‐III | 86 | 89 | 86 | 125 | 73 | 100 | 106 |
| HGP46 | 852 | C‐III | 23 | 91 | 88 | 127 | 76 | 37 | 108 |
| HGP47 | 853 | C‐III | 87 | 89 | 86 | 128 | 77 | 103 | 106 |
| HGP48 | 852 | C‐III | 23 | 91 | 88 | 127 | 76 | 37 | 108 |
| HGP71 | 848 | C‐III | 86 | 89 | 86 | 125 | 73 | 100 | 106 |
| HGP78‐1 | 632 | C‐III | 57 | 61 | 61 | 90 | 50 | 71 | 83 |
| HGP78‐2 | 848 | C‐III | 86 | 89 | 86 | 125 | 73 | 100 | 106 |
| HGP79 | 848 | C‐III | 86 | 89 | 86 | 125 | 73 | 100 | 106 |
Source: 1 (soil); 2 (shoes); 3 (compost), ST: Sequence type, RT: Ribotype, TP: Toxin profile.
FIGURE 3Global phylogenetic context of seven novel sequence types. MLST phylogeny based on concatenated allele sequences for seven novel sequence types (cryptic clade C‐III) and well‐characterized representatives of MLST clade 1 (ST54, RT012), clade 2 (ST1, RT027), clade 3 (ST22, RT023), clade 4 (ST37, RT017), clade 5 (ST11, RT078), as well as other cryptic clades C‐I (ST360) and C‐II (ST200). The scale shows the number of substitutions per site
FIGURE 4PaLoc structure of tcdA‐positive isolates of C. difficile from environmental samples. Mono‐toxin PaLoc of environmental isolates (e.g. HGP14) shared synteny and a high nucleotide sequence similarity to the PaLoc of clinical isolate RA09‐70 (clade 5)
Core genome SNP analysis
Heatmap of pairwise core genome SNP differences between 17 isolates: 0‐20, 21‐100, 101‐3000, 3001‐6000 and 6001‐7000.
aST: Sequence type, bRT: Ribotype, cTP: Toxin profile, dSource: 1 (soil); 2 (shoes); 3 (compost).
[Correction added on 20th April 2022, after first online publication: Table 5 footnotes have been included]